Inventor
SCOTT WILLIAM J
45 patents
⚠️ This page may combine multiple inventors who share the name “SCOTT WILLIAM J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IDEAL IND
9 patentsUS4532679AAug 6, 1985
Cable tie
IDEAL IND41 citations93
US4112251ASep 5, 1978
Screw-on wire connector and method of making it
IDEAL IND35 citations93
US4227040AOct 7, 1980
Screw-on electrical connector
IDEAL IND27 citations82
US4220811ASep 2, 1980
Screw-on electrical connector
IDEAL IND20 citations82
US4104482AAug 1, 1978
Screw-on connector
IDEAL IND22 citations82
US4549038AOct 22, 1985
Cord grip
IDEAL IND25 citations78
US4350841ASep 21, 1982
Electrical connector
IDEAL IND12 citations74
US4150251AApr 17, 1979
Screw-on wire connectors
IDEAL IND8 citations74
US3973821AAug 10, 1976
Connector
IDEAL IND17 citations73
BAYER HEALTHCARE LLC
8 patentsUS7678811B2Mar 16, 2010
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
BAYER HEALTHCARE LLC57 citations98
US7838541B2Nov 23, 2010
Aryl ureas with angiogenesis inhibiting activity
BAYER HEALTHCARE LLC55 citations96
US7897623B2Mar 1, 2011
ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
BAYER HEALTHCARE LLC35 citations92
US7625915B2Dec 1, 2009
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
BAYER HEALTHCARE LLC33 citations92
US7557129B2Jul 7, 2009
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
BAYER HEALTHCARE LLC18 citations91
US7928227B2Apr 19, 2011
2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders
BAYER HEALTHCARE LLC10 citations84
US7928239B2Apr 19, 2011
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
BAYER HEALTHCARE LLC15 citations83
US10653684B2May 19, 2020
Aryl ureas with angiogenisis inhibiting activity
BAYER HEALTHCARE LLC0 citations51
BAYER PHARMACEUTICALS CORP
6 patentsUS7329670B1Feb 12, 2008
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
BAYER PHARMACEUTICALS CORP76 citations97
US7235576B1Jun 26, 2007
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
BAYER PHARMACEUTICALS CORP94 citations97
US6849638B2Feb 1, 2005
4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
BAYER PHARMACEUTICALS CORP36 citations91
US7517880B2Apr 14, 2009
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
BAYER PHARMACEUTICALS CORP25 citations90
US6784167B2Aug 31, 2004
17-beta-hydroxysteroid dehydrogenase-II inhibitors
BAYER PHARMACEUTICALS CORP35 citations89
US7371763B2May 13, 2008
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
BAYER PHARMACEUTICALS CORP17 citations83
DUMAS JACQUES
6 patentsUS8071616B2Dec 6, 2011
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
DUMAS JACQUES48 citations94
US8618141B2Dec 31, 2013
Aryl ureas with angiogenesis inhibiting activity
DUMAS JACQUES20 citations91
US8242147B2Aug 14, 2012
Aryl ureas with angiogenisis inhibiting activity
DUMAS JACQUES17 citations91
US8076488B2Dec 13, 2011
Bicyclic urea derivatives useful in the treatment of cancer and other disorders
DUMAS JACQUES10 citations82
US8110587B2Feb 7, 2012
Aryl ureas as kinase inhibitors
DUMAS JACQUES8 citations79
US9181188B2Nov 10, 2015
Aryl ureas as kinase inhibitors
DUMAS JACQUES3 citations57
BAYER AG
3 patentsUS6911443B2Jun 28, 2005
Imidazopyrimidine derivatives and triazolopyrimidine derivatives
BAYER AG32 citations90
US6353006B1Mar 5, 2002
Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
BAYER AG33 citations88
US5932763AAug 3, 1999
Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids
BAYER AG6 citations55